Joo‐Hee Yi

Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer

Ian E. Krop, Muralidhar Beeram, Shanu Modi et al. · Journal of Clinical Oncology · 2010 · 596 citations

Medicine, Oncology, Pharmacology +17

A target‐mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans

Stephen M. Eppler, Daniel L. Combs, Timothy D. Henry et al. · Clinical Pharmacology & Therapeutics · 2002 · 269 citations

Medicine, Pharmacokinetics, Pharmacology +14

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer

Sandhya Girish, Manish Gupta, Bei Wang et al. · Cancer Chemotherapy and Pharmacology · 2012 · 265 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Preclinical safety profile of trastuzumab emtansine (T-DM1): Mechanism of action of its cytotoxic component retained with improved tolerability

Kirsten Achilles Poon, Kelly M. Flagella, Joseph C. Beyer et al. · Toxicology and Applied Pharmacology · 2013 · 194 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody–drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates

Dan Lu, Sandhya Girish, Yuying Gao et al. · Cancer Chemotherapy and Pharmacology · 2014 · 85 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17